Skip to main content

Table 2 Children’s health status and vaccination coverage in rural Andean Peru

From: A factorial cluster-randomised controlled trial combining home-environmental and early child development interventions to improve child health and development: rationale, trial design and baseline findings

 

IHIP+

IHIP

ECD

Control

N

Mean (SD)

or % (N)

N

Mean (SD)

or % (N)

N

Mean (SD)

or % (N)

N

Mean (SD)

or % (N)

Anthropometricsa

78

 

79

 

79

 

81

 

 Height-for-age, Z-values

64

− 1.3 (1.1)

50

−1.0 (0.9)

64

−1.5 (1.1)

61

−1.4 (0.8)

 Stunting

64

17.2% (11)

50

9.8% (5)

64

36.9% (24)

61

18.0% (11)

 Weight-for-age, Z-scores

64

−0.4 (1.0)

51

− 0.1 (0.8)

65

− 0.6 (0.9)

61

− 0.5 (0.9)

 Underweight

64

6.3% (4)

51

2.0% (1)

65

10.8% (7)

61

4.9% (3)

Children’s health status

78

 

79

 

79

 

81

 

 Weight at birth

 

3.1 (0.6)

 

3 (0.5)

 

3.1 (0.5)

 

3.1 (0.4)

 Diarrhoea, two-weeks prevalence

 

18.4% (14)

 

22.8% (18)

 

19% (15)

 

26.3% (21)

 Fever, two-weeks prevalence

 

21.8% (17)

 

21.5% (17)

 

25.3% (20)

 

23.5% (19)

 Cough, two-weeks prevalence

 

35.1% (27)

 

31.7% (25)

 

39.2% (31)

 

29.1% (23)

 Children with no health coverage

 

10.3% (8)

 

10.1% (8)

 

5.1% (4)

 

1.2% (1)

Children’s vaccination

78

 

79

 

79

 

81

 

 Tuberculosis (BCG)

77

89.6% (69)

 

91.1% (72)

 

94.9% (75)

 

95.1% (77)

 Measles

77

50.7% (39)

78

60.3% (47)

77

67.5% (52)

 

64.2% (52)

 Diphtheria, convulsive cough and tetanus (DTP)b

  1st dose

77

96.1% (74)

 

94.9% (75)

 

98.7% (78)

 

95.1% (77)

  2nd dose

73

90.4% (66)

77

89.6% (69)

 

97.5% (77)

79

93.7% (74)

  3rd dose

64

87.5% (56)

69

79.7% (55)

72

93.1% (67)

73

82.2% (60)

 Polio (OPV)c

        

  1st dose

77

96.1% (74)

 

96.2% (76)

 

98.7% (78)

 

96.3% (78)

  2nd dose

73

89.0% (65)

77

90.9% (70)

 

97.5% (77)

79

93.7% (74)

  3rd dose

64

78.1% (50)

69

79.7% (55)

72

90.3% (65)

73

75.3% (55)

 Influenza

77

62.3% (48)

 

63.3% (50)

 

81.0% (64)

 

69.1% (56)

 Hepatitis B

77

62.3% (48)

 

54.4% (43)

 

79.8% (63)

 

69.1% (56)

Recommended vaccines 6–11 months

23

 

28

 

24

 

15

 

 All vaccinesd

 

69.6% (16)

 

60.7% (17)

 

87.5% (21)

 

40% (6)

 No vaccines

 

0% (0)

 

7.1% (2)

 

0% (0)

 

0% (0)

Recommended vaccines 12–24 months

41

 

41

 

48

 

58

 

 All vaccinese

 

68.3% (28)

 

70.7% (29)

46

84.8% (39)

 

70.7% (41)

 No vaccines

 

2.4% (1)

 

4.9% (2)

 

2.1% (1)

 

0% (0)

Portable pulse oximetry assessmentf

64

 

59

 

63

 

68

 

 Oxygen saturation (SpO2)

 

93.5 (2.8)

 

94.2 (2.5)

 

93.8 (3.8)

 

93.8 (2.8)

 Respiratory rate per/min.

 

27.7 (3.7)

 

26.4 (3.0)

 

27.2 (2.7)

 

27.3 (3.1)

  1. 1As estimated on 15th December 2015 (±31 days). If several estimates within the range were available, the one closest to 15th of December was selected
  2. bDPT vaccination: 1st dose: 2 month; 2nd dose: 4 month; and 3rd dose: 6 month
  3. c Polio vaccination: 1st dose: 2 month; 2nd dose: 4 month; and 3rd dose: 6 month
  4. d It includes BCG (one dose), DTP (three doses) and OPV (three doses)
  5. e It includes BCG (one dose), DTP (three doses), OPV (three doses) and measles (one dose)
  6. f Results from children with no observable danger signs, fever, cough and difficulty to breath at the time of the assessment